Jonathan Rubin - 27 Dec 2024 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Reporting relationship: SVP, Chief Medical Officer
Issuer ticker: SUPN
Reported as of: 27 Dec 2024
Net transaction value: -$39,220
SEC form: 4
Accepted by SEC: 30 Dec 2024, 16:13:12 UTC
Prior SEC filing: 26 Dec 2024
Next SEC filing: 29 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Timothy C. Dec, as attorney-in-fact

Key filing fact

Jonathan Rubin filed Form 4 for SUPERNUS PHARMACEUTICALS, INC. (SUPN) on 30 Dec 2024.

Key facts

This page summarizes Jonathan Rubin's Form 4 filing for SUPERNUS PHARMACEUTICALS, INC. (SUPN).
6 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 30 Dec 2024, 16:13.

Change

Previous filing in this sequence was filed on 26 Dec 2024.
Current net transaction value: -$39,220.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SUPN transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +750
Change %: +15%
Price: $0.000000
Shares after: 5,822
Date: 27 Dec 2024
Ownership: Direct
Footnotes: F1, F2

SUPN transaction

Common Stock

Tax liability

Transaction value: $10,001
Shares: -281
Change %: -4.8%
Price: $35.59
Shares after: 5,541
Date: 27 Dec 2024
Ownership: Direct
Footnotes: F3

SUPN transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +1,875
Change %: +34%
Price: $0.000000
Shares after: 7,416
Date: 27 Dec 2024
Ownership: Direct
Footnotes: F4

SUPN transaction

Common Stock

Tax liability

Transaction value: $29,219
Shares: -821
Change %: -11%
Price: $35.59
Shares after: 6,595
Date: 27 Dec 2024
Ownership: Direct
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SUPN transaction Derivative

Performance Share Unit

Options Exercise

Transaction value: $0
Shares: -750
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 27 Dec 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 750
Exercise price: $0.000000
Footnotes: F5

SUPN transaction Derivative

Performance Share Unit

Options Exercise

Transaction value: $0
Shares: -1,875
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 27 Dec 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,875
Exercise price: $0.000000
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 23, 2023.

Footnote F2

Includes an aggregate of 431 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.

Footnote F3

Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.

Footnote F4

Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 22, 2024.

Footnote F5

On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023 and modified on December 12, 2024.

Footnote F6

On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024.